Biomarkers in systemic sclerosisSkaug, Brian; Assassi, ShervinCurrent Opinion in Rheumatology: November 2019 - Volume 31 - Issue 6 - p 595–602 doi: 10.1097/BOR.0000000000000656 RAYNAUD PHENOMENON, SCLERODERMA, OVERLAP SYNDROMES AND OTHER FIBROSING SYNDROMES: Edited by John Varga Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review To discuss recent advances in identification of biomarkers in systemic sclerosis for disease severity, prognosis, and treatment response. Recent findings Recent reports describe novel circulating markers of disease severity, autoantibody associations with specific manifestations including cancer, and skin gene expression-based predictors of modified Rodnan skin score progression and treatment response. Moreover, there is converging evidence that C-reactive protein and pneumoproteins such as Krebs von den Lungen-6 and chemokine ligand 18 could serve as prognostic biomarkers in systemic sclerosis-associated interstitial lung disease. Summary Several novel biomarkers show promise in improving the assessment of systemic sclerosis (SSc) disease severity, prognosis, and treatment response. Their potential utility in prospective selection of patients for clinical trials and in individual patient management require additional research. Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas Health Science Center Houston, Houston, Texas, USA Correspondence to Shervin Assassi, Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas Health Science Center Houston, 6431 Fannin, MSB 5.270, Houston, TX 77030, USA. Tel: +1 713 500 6883; e-mail: Shervin.Assassi@uth.tmc.edu Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.